Mohri K, Nagai H, Mukozu T, Matsui T, et al. Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights. Anticancer Res 2026;46:1545-1556.
PMID: 41760263